Evaluable patients | 17 |
Complete Response | 0 |
Partial Response | 0 |
Stable Disease | 12 |
Disease Progression | 4 |
Not Evaluable | 1 |
Overall Response Rate | 0 |
Disease Control Rate | 70.6 % |
- Evaluable Patients: The full analysis set (FAS) of 17 includes patients who received at least one dose of TP300 and had at least one measurable target-lesion confirmed by independent review committee (IRC)
- Not Evaluable: 1 patient did not have a post dose tumour radiological assessment, so could not be assessed
- Note: A further 2 patients who received TP300 were excluded from the FAS, as the target lesion/s could not be confirmed by IRC